Explore more price target data and ratings for Neurocrine Biosciences, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Neurocrine Biosciences, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research System…
Q2 2026 saw record revenues exceeding $950 million, driven by strong performances from INGREZZA, CRENESSITY, and the newly acquired VYKAT XR. The company raised full-year guidance, advanced its pipeline, and maintained robust financial health with no debt and significant cash reserves.Based on Neur…
Q2 2026 saw record revenues exceeding $950 million, driven by strong performances from INGREZZA, CRENESSITY, and the newly acquired VYKAT XR. Guidance for INGREZZA was raised, and the company remains on track for key clinical milestones in 2027, with robust financial flexibility and expanding marke…
Second-quarter 2026 revenue rose 39% year-over-year to $959 million, driven by strong growth in INGREZZA, CRENESSITY, and the addition of VYKAT XR post-Soleno acquisition. Full-year INGREZZA sales guidance was raised, and new clinical milestones are expected in 2027.Original document: Neurocrine Bi…
Neurocrine Biosciences NBIX continues to strengthen its growth profile through the solid commercial performance of its marketed therapies, a steadily advancing late-stage neuroscience pipeline and strategic business development initiatives.Strong Commercial Performance Aids NBIX’s GrowthNeurocrine…
